The link between obesity and prostate cancer: the leptin pathway and therapeutic perspectives.
Obesity-associated prostate cancer (PCa) remains controversial, although most studies rely on body mass index evaluation, which is an indirect measure of fatness. Studies using body fat measurement and disease stratification according to PCa stage found stronger associations between obesity and PCa. Leptin is a pleiotrophic hormone mainly synthesized by adipocytes that acts in peripheral organs such as the prostate. This article reviews obesity-associated leptin's pathophysiological role in PCa progression. PCa development results from some known risk factors. Currently, there is enough evidence suggesting that leptin is an additional factor involved in advanced PCa occurrence, and obesity association with high-grade disease. Life-long exposure to genetic and/or environmental susceptibility factors that predispose to obesity and higher leptin levels may increase the risk for advanced PCa.
Ribeiro
R
R
Molecular Oncology--CI, Oncology Portuguese Institute, Porto, Portugal.
Lopes
C
C
Medeiros
R
R
D018890:Chemoprevention; D006801:Humans; D020738:Leptin / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000150:complications* / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000209:etiology / Q000517:prevention & control; D015398:Signal Transduction
D020738:Leptin